Prostate cancer is the second most common cancer in men, accounting for around 15% of all cancer cases in the male population. In many parts of the world, it’s the most common form of cancer in men.
Advances in research into prostate cancer
Prostate cancer has been the focus of a huge amount of research in recent years. We have seen huge advances in treatment for the disease, including robot-assisted surgery, high precision radiotherapy, and many new therapies for advanced disease.
The revolution in genomic tools has been central to advances in this field of research. These are likely to become more important in treatment decisions, as are advances in imaging, particularly PSMA-PET-CT.
Both imaging and DNA technologies are potentially scalable, affordable and often widely available in lower to middle income countries. The challenge lies in identifying the how to best deploy these technologies. These types of changes have cost and delivery challenges for all healthcare systems. But they also present opportunities to reshape and optimise care.
Aims of the commission
The Lancet commission aims to:
- explore the optimal changes to treating prostate cancer
- provide advice on what's likely to be the best approach in different healthcare settings
- make policy and clinical practice recommendations
- make recommendations for future global investment and research priorities
Researchers on the commission
Nick James will be supported in the commission by four working group chairs: Professor Ian Tannock, Professor James N’Dow, Professor Felix Feng and Professor Silke Gillessen. The target publication date is 2022.
Read the launch article
See full list of commissioners
Feedback to the commission
The commission intends to be open and to seek inputs from as broad a range of sources as possible from around the globe. We welcome input and comments; if you would like to get in touch please email [email protected].